# Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

> **NCT01324492** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Lung Neuroendocrine Neoplasm

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT01324492
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324492, "Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01324492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*